Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: The SAFE-ES study

Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), 2012, ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Eur Heart J, 33, 2569, 10.1093/eurheartj/ehs215 Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, Lancet, 364, 937, 10.1016/S0140-6736(04)17018-9 Verschuren, 1995, Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five years follow-up of the seven countries study, JAMA, 274, 131, 10.1001/jama.1995.03530020049031 Chen, 1991, Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations, BMJ, 303, 276, 10.1136/bmj.303.6797.276 O’Keefe, 2004, Optimal low-density lipoprotein is 50 to 70mg/dL. Lower is better and physiologically normal, J Am Coll Cardiol, 43, 2142, 10.1016/j.jacc.2004.03.046 Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E Jankowski, 2007, Ezetimibe: new perspectives in lipid lowering treatment, Cardiol J, 14, 232 Davis, 2007, Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treathyperlipidemia, J Atheroscler Thromb, 14, 99, 10.5551/jat.14.99 Kashani, 2008, Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials, Am J Cardiol, 101, 1606, 10.1016/j.amjcard.2008.01.041 Stein, 2004, Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe coadministered with atorvastatin, Am Heart J, 148, 447, 10.1016/j.ahj.2004.03.052 Bissonnette, 2006, Efficacy and tolerability of ezetimibe 10mg/day coadministered with statins in patients with primary hypercholesterolemeia who do not achieve target LDL-C while on statin monotherapy: a Canadian, multicentre, prospective study – the Ezetrol Add-On Study, Can J Cardiol, 22, 1035, 10.1016/S0828-282X(06)70319-1 Mikhailidis, 2007, Meta-analysis of the cholesterol- lowering effect of ezetimibe added to ongoing statin therapy, Curr Med ResOpin, 23, 2009, 10.1185/030079907X210507 Hamm, 2011, Eur Heart J, 32, 2999, 10.1093/eurheartj/ehr236 McKenney, 2006, Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force, Am J Cardiol, 97, 89C, 10.1016/j.amjcard.2006.02.030 Melani, 2003, Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial, Eur Heart J, 24, 717, 10.1016/S0195-668X(02)00803-5 Ballantyne, 2007, Efficacy and safety of rosuvastatin 40mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study), Am J Cardiol, 99, 673, 10.1016/j.amjcard.2006.10.022 Davidson, 2004, Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia, Int J Clin Pract, 58, 746, 10.1111/j.1368-5031.2004.00289.x Fleg, 2008, Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial, J Am Coll Cardiol, 52, 2198, 10.1016/j.jacc.2008.10.031 Mikhailidis, 2011, Comparative efficacy of the addition of ezetimibe to statin vs. statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis, Curr Med Res Opin, 27, 1191, 10.1185/03007995.2011.571239 Commission de transparence de la Haute Autorité de santé. Available at: http://www.has-sante.fr/portail/jcms/c_997109/crestor-ct-8369. Accessed October 1, 2010. Cannon, 2004, Intensive versus moderate lipid lowering withstatins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583 Davidson, 2006, Statin safety: an appraisal from the adverse event reporting system, Am J Cardiol, 97, 32C, 10.1016/j.amjcard.2005.12.008 Kastelein, 2008, Simvastatin with or without ezetimibe in familial hypercholesterolemia, N Engl J Med, 358, 1431, 10.1056/NEJMoa0800742 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 2002, Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 Roy, 2008, Impact of “nuisance” bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation, Am J Cardiol, 102, 1614, 10.1016/j.amjcard.2008.07.063 Jernberg, 2011, Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction, JAMA, 305, 1677, 10.1001/jama.2011.522 Stein, 2008, Efficacy and tolerability of fluvastatin XL 80mg alone, ezetimibe alone, and the combination of fluvastatin XL 80mg with ezetimibe in patients with a history of muscle-related side effects with other statins, Am J Cardiol, 101, 490, 10.1016/j.amjcard.2007.09.099 Shek, 2001, Statin-fibrate combination therapy, Ann Pharmacother, 35, 908, 10.1345/aph.10315 De Lemos, 2004, Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial, JAMA, 292, 1307, 10.1001/jama.292.11.1307 European Association for Cardiovascular Prevention & Rehabilitation, 2011, ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur Heart J, 32, 1769, 10.1093/eurheartj/ehr158 Cannon, 2008, Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes, Am Heart J, 156, 826, 10.1016/j.ahj.2008.07.023